Navigation Links
Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
Date:5/24/2013

BEIJING, May 24, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility. The GMP certificate covers Sinovac Beijing's vaccines commercialized in China and approved for stockpiling, inclusive of hepatitis A vaccine (human diploid cell), inactivated; hepatitis A and B combined vaccine; influenza vaccine (split virion), inactivated; pandemic influenza vaccine (inactivated, adjuvanted); pandemic influenza vaccine (split virion, adjuvanted); H1N1 influenza A vaccine (Split Virion, inactivated) The GMP certificate is valid for five years starting from April 17, 2013.

New GMP standards were implemented in China by the CFDA in March 2011. These new standards are in line with international standards. According to the notice for the implementation of new GMP guidelines (2010 version) issued by CFDA in February 2011, all China-based vaccine manufacturers are required to pass the new GMP certification by the end of 2013.

In December 2012, the CFDA conducted a on-site inspection on Sinovac Beijing's production plants in Haidian district and the new filling and packaging line in Changping district according to the Good Manufacturing Practice for Drugs (2010 Revision), the new GMP guidelines. The CFDA granted Sinovac the GMP Certification in April 2013 following the March 2013 public notification period.

Dr. Weidong YIN, Chairman,
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
2. Sinovac Reports Unaudited First Quarter 2012 Financial Results
3. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
4. Sinovac Schedules 2012 Annual Meeting of Shareholders
5. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Sinovac Holds 2012 Annual General Meeting of Shareholders
8. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
9. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
10. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
11. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Nov. 1 The Phase 3 results from the ... therapy regimens. The study reports an improvement in treatment ... 2 studies, and demonstrates an increase in sustained viral ... The primary endpoint for this study was SVR 24 ...
... Nov. 1, 2010 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 3Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 2Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 3Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 4Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 5Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 6Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 7Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 8Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 9Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 10Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 11Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 12
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Nov. 7 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that it will release its financial results for,the quarter ... after,the close of the U.S. financial markets. CryoCor ... at 5:00 p.m. ET /,2:00 p.m. PT on November ...
... With Business Objectives, Watson ... Survey Finds, WASHINGTON, Nov. 7 With continuing ... offer financial,incentives to reward workers who adopt healthy lifestyles, ... global consulting firm, and the,National Business Group on Health, ...
... 7 A cholesterol-lowering drug appears to disrupt sleep ... Heart Associations Scientific Sessions 2007. , The findings are ... and may have adverse health consequences, such as promoting ... lead author of the study and an associate professor ...
... Nov. 7 Exposing estrogen-sensitive breast cancer cells to ... sewer and industrial waste causes the cells to multiply, ... at the annual meeting of the American Public Health ... will be presented at a special session on Contaminants ...
... Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. 7 ... Philip Morris and R.J. Reynolds tobacco companies have,again ... by defeating a,ballot initiative to increase Oregon,s cigarette ... companies will profit by selling more cigarettes,while Oregonians ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... Operating Officer, will present at the JMP Securities,Healthcare ... 2007 at 2:30 p.m.,Eastern Time. To access ... visit the Investor Relations section of Genomic Health,s,website ...
Cached Medicine News:Health News:CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 3Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2Health News:Extracts of catfish caught in polluted waters cause breast cancer cells to multiply 2Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Genomic Health to Present at JMP Securities Healthcare Focus Conference 2
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Graduat...
Medicine Products: